Democritus University of Thrace, Faculty of Agricultural Development, Department of Food Science and Technology, Laboratory of Microbiology, Biotechnology and Hygiene, Pantazidou 193, Orestiada GR68200, Greece.
Anaerobe. 2011 Dec;17(6):391-3. doi: 10.1016/j.anaerobe.2011.02.010. Epub 2011 Apr 14.
Resistant pathogens are the cause of clinical infections which threatening the patients lives and challenging the health systems through their economic importance. Therefore, new antibacterial agents with a broader spectrum of activity that protect against development of resistance are required. Tigecycline (Tygacil, Wyeth) is a relatively new FDA and EMEA approved glycylcycline antimicrobial with an expanded broad-spectrum activity against pathogens involved in complicated skin and skin structure infections. In this study we evaluated the in vitro activity of tigecycline in comparison to 14 other antibiotics against 182 clinical pathogens by use of the micro dilution method. In overall, tigecycline exhibited the lowest Minimum Inhibitory Concentration (MIC) values in almost all bacteria with a mean of 0.52 ± 1.25mg/L, followed by meropenem and levofloxacin (mean MIC values 1.29 ± 2.52 and 1.45 ± 3.078 mg/L, respectively). MIC50 and MIC90 values of tigecycline were: 0.06 and 0.15 mg/L for E. coli, 0.12 and 1.00 mg/L for Klebsiella sp., 0.12 and 0.85 mg/L for various Enterobacter sp., 1.00 and 8.00 mg/L for Pseudomonas sp., 0.25 and 1.00 mg/L for Acinetobacter sp., 0.06 and 0.12 mg/L for Serratia sp., 0.12 and 0.25mg/L for Staphylococcus aureus, 0.5 and 5.00 mg/L for Streptococcus sp. The MIC values recorded were among the lowest in recent literature for Acinetobacter sp. (included A. baumannii), and comparable to those obtained for Klebsiella, Serratia and Enterobacter indicating that tigecycline has a promising in vitro activity.
耐药病原体是导致临床感染的原因，它们通过其经济重要性威胁着患者的生命并挑战着卫生系统。因此，需要具有更广泛作用谱的新型抗菌药物来预防耐药性的产生。替加环素（泰阁，惠氏）是一种相对较新的美国食品和药物管理局和欧洲药品管理局批准的甘氨酰环素抗菌药物，对涉及复杂皮肤和皮肤结构感染的病原体具有广泛的扩展活性。在这项研究中，我们通过微量稀释法评估了替加环素与其他 14 种抗生素对 182 种临床病原体的体外活性。总的来说，替加环素在几乎所有细菌中的最低抑菌浓度（MIC）值最低，平均为 0.52±1.25mg/L，其次是美罗培南和左氧氟沙星（平均 MIC 值分别为 1.29±2.52 和 1.45±3.078mg/L）。替加环素的 MIC50 和 MIC90 值为：大肠埃希菌为 0.06 和 0.15mg/L，克雷伯氏菌属为 0.12 和 1.00mg/L，各种肠杆菌属为 0.12 和 0.85mg/L，铜绿假单胞菌为 1.00 和 8.00mg/L，鲍曼不动杆菌为 0.25 和 1.00mg/L，粘质沙雷氏菌为 0.06 和 0.12mg/L，金黄色葡萄球菌为 0.12 和 0.25mg/L，链球菌属为 0.5 和 5.00mg/L。对于鲍曼不动杆菌（包括鲍曼不动杆菌），记录的 MIC 值在最近的文献中是最低的，与克雷伯氏菌、粘质沙雷氏菌和肠杆菌属获得的 MIC 值相当，这表明替加环素有良好的体外活性。
